Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.
about
Wide range of quasispecies diversity during primary hepatitis C virus infectionEarly changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcomeViral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.Plasma and Liver Hepatitis C Virus Variability in Patients Coinfected with Human Immunodeficiency VirusViral Determinants of Resistance to Treatment in Patients with Hepatitis CSignificance of Pretreatment Analysis of Hepatitis C Virus Genotype 1b Hypervariable Region 1 Sequences To Predict Antiviral OutcomeNew Natural Intergenotypic (2/5) Recombinant of Hepatitis C VirusCorrelation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3aFrequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes.Cloning and identification of NS5ATP2 gene and its spliced variant transactivated by hepatitis C virus non-structural protein 5A.Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcomeCharacterization of hepatitis C Virus genotype 3a hypervariable region 1 in patients achieved rapid virological response to alpha interferon and ribavirin combination therapy.Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patientsExpression of hepatitis C virus hypervariable region 1 and its clinical significance.Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis CEvidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy.High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy.Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.A cluster of hepatitis C virus infections associated with ozone-enriched transfusion of autologous blood in Rome, Italy.Efficacy of consensus interferon in the treatment of chronic hepatitis C.Iatrogenic transmission of hepatitis C virus (HCV) by an anesthesiologist: comparative molecular analysis of the HCV-E1 and HCV-E2 hypervariable regions.Genetic heterogeneity of the envelope 2 gene and eradication of hepatitis C virus after a second course of interferon-alpha.Hepatitis C virus: Morphogenesis, infection and therapy.
P2860
Q27469430-A6668549-83B8-4CF2-842F-19C5636105EDQ27471683-B963CD7E-B19F-4470-BC40-DA64485E58B1Q27472893-DD0F52EB-F82C-45C5-8429-09CE9E79E611Q27473249-A029AC57-FF0B-4F4F-991D-CE5B6727ADF7Q27478062-2663E39E-A98F-4D74-A28C-F0104B7FB78BQ27478087-DAD8E819-A42C-4BF9-9018-EE9EFCFA0175Q27478380-94D775AE-982C-40E3-A114-9A1B7A9B9930Q27486521-BE4865E3-A910-4C27-9874-0452FF837753Q30758796-E28F1FDB-C074-4BFE-8A8B-A073E6903751Q31076761-B6FD4EDE-6F0E-4F6B-8124-97226313F61FQ33834509-87397DFC-9AD2-444A-A346-70F03086711BQ34485144-6F0FF4B9-0E8A-471A-A6A4-FC3E696CF973Q35053127-D3D0918C-7545-48C6-93CE-14EC47E5A1A2Q35077010-DDD38F0A-53D0-41A8-97A8-90323A9F2F24Q36178437-05713E9C-82FE-4290-87FD-0E5491BC4FAAQ36178690-E227BDC7-E1F5-4011-BB83-62C88F4E3748Q41115175-13214C0C-7AA1-41EB-8A88-591BD630949FQ42661814-E5D81941-2D00-4284-B814-61F1AEADBE39Q42731526-8A00DF77-BD14-4526-AB00-AB00B086F3A0Q42995672-20208C56-8B3F-4F73-B1A3-4B25E4323A4FQ43029839-7F5D05B7-3C27-493C-8410-2C1ADBA701A9Q43039380-D00747FF-9C3C-4A68-B8F8-55E42A0180B5Q43039761-B795E2B6-393D-496A-832E-537194DFCD19Q52661702-D1E2CAC0-C8A8-4555-B795-05252FAC51A2
P2860
Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Genetic heterogeneity of hyper ...... CV to alpha interferon therapy
@nl
Genetic heterogeneity of hyper ...... V to alpha interferon therapy.
@ast
Genetic heterogeneity of hyper ...... V to alpha interferon therapy.
@en
type
label
Genetic heterogeneity of hyper ...... CV to alpha interferon therapy
@nl
Genetic heterogeneity of hyper ...... V to alpha interferon therapy.
@ast
Genetic heterogeneity of hyper ...... V to alpha interferon therapy.
@en
prefLabel
Genetic heterogeneity of hyper ...... CV to alpha interferon therapy
@nl
Genetic heterogeneity of hyper ...... V to alpha interferon therapy.
@ast
Genetic heterogeneity of hyper ...... V to alpha interferon therapy.
@en
P2093
P2860
P1433
P1476
Genetic heterogeneity of hyper ...... V to alpha interferon therapy.
@en
P2093
C Pasquier
J P Pascal
P2860
P304
P356
10.1128/JVI.74.2.661-668.2000
P577
2000-01-01T00:00:00Z